Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
NCT04520217

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Led by Wright State University · Updated on 2025-01-27

40

Participants Needed

1

Research Sites

234 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).

CONDITIONS

Official Title

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Who Can Participate

Age: 18Years - 50Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Female and male adults aged 18 to 50
  • Able to give informed consent
  • Have stable transportation access
  • All skin types on Fitzpatrick Scale (Type I-VI)
  • Self-identified photosensitivity
  • Able to provide medical history and list of medications; control subjects not taking photosensitizing medications
Not Eligible

You will not qualify if you...

  • Underlying diseases affecting wound healing (e.g., uncontrolled diabetes mellitus)
  • Taking photosensitizing medications (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDs except low-dose aspirin, steroids)
  • Using imipramine or other tricyclic antidepressants (oral or cream)
  • Using topical anti-inflammatory or systemic agents (e.g., prednisone)
  • Large tattoos in testing areas
  • Tanning bed use within last 3 months
  • Photodynamic therapy or UVB treatments in last 3 months
  • Female subjects who are pregnant or nursing
  • History of abnormal scarring such as keloids

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Wright State Physicians

Fairborn, Ohio, United States, 45324

Actively Recruiting

Loading map...

Research Team

M

Manager Clinical Research Operations

CONTACT

R

Regulatory Specialist

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects | DecenTrialz